Hypermarcas (OTCMKTS:HYPMY) Upgraded at Jefferies Financial Group

Hypermarcas (OTCMKTS:HYPMY) was upgraded by research analysts at Jefferies Financial Group to a “strong-buy” rating in a note issued to investors on Monday,Zacks.com reports.

Separately, Zacks Research raised shares of Hypermarcas to a “hold” rating in a research note on Wednesday, April 29th. One investment analyst has rated the stock with a Strong Buy rating and one has issued a Hold rating to the company. Based on data from MarketBeat.com, the stock has an average rating of “Buy”.

Hypermarcas Price Performance

Hypermarcas stock opened at $4.04 on Monday. Hypermarcas has a 1-year low of $3.71 and a 1-year high of $5.50. The company has a market cap of $2.84 billion, a PE ratio of 8.41 and a beta of 0.71. The stock’s 50 day moving average price is $4.18 and its 200 day moving average price is $4.39.

Hypermarcas (OTCMKTS:HYPMY) last released its quarterly earnings data on Wednesday, April 29th. The company reported $0.10 earnings per share (EPS) for the quarter. The firm had revenue of $383.13 million during the quarter. Hypermarcas had a return on equity of 14.08% and a net margin of 19.41%. On average, equities research analysts anticipate that Hypermarcas will post 0.53 EPS for the current fiscal year.

Hypermarcas Company Profile

Hypermarcas SA is a Brazil-based consumer health and pharmaceutical company whose shares trade over the counter in the United States under the symbol HYPMY. Founded in the early 2000s and headquartered in Rio de Janeiro, the company operates as a holding group for a broad portfolio of branded products in the healthcare and personal care sectors.

Through its various subsidiaries, Hypermarcas develops, manufactures and markets prescription and over-the-counter medications, alongside personal care, baby care, home care and nutritional supplement products.